Skip to main content





 Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policy (CP224). November 2021 (PDF, 443Kb)
 Brachytherapy in the Treatment of Localised Prostate Cancer, Commissioning Policy (CP01). September 2022 (PDF, 368Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®) Service Specification (CP175). March 2019 (PDF, 514Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification. (CP176). March 2019 (PDF, 571Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement, (PP185). April 2023 (PDF, 254Kb)
 CP86 Services for Children with Cancer.pdf (PDF, 585Kb)
 CP98 Eculizimab for Atypical Haemolytic Uraemic Syndrome (aHUS).pdf (PDF, 319Kb)
 Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis and Pseudomyxoma Peritonei, Policy Position Statement, (PP90). September 2015 (PDF, 239Kb)
 Eculizumab in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), Commissioning Policy, (CP152), July 2023 (PDF, 641Kb)
 Enhanced Image Guided Brachytherapy (IGBT) Service for the Treatment of Gynaecological Malignancies, Commissioning Policy (CP75). May 2017 (PDF, 723Kb)
 Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023 (PDF, 288Kb)
 Extracorporeal Photophoresis (ECP )for treatment of Chronic Graft Versus Host Disease GVHD in Adults Commissioning Policy, (CP91). November 2015 (PDF, 231Kb)
 Extracorporeal Photophoresis (ECP) for T Cell lymphoma, Commissioning Policy (CP92). November 2015 (PDF, 192Kb)
 Genomic Services, Service Specification (CP99), June 2022 (PDF, 572Kb)
 Haematopoietic stem cell transplantation for adults, Service Specification (CP79). January 2020 (PDF, 295Kb)
 Haematopoietic stem cell transplantation, Policy Position Statement, (PP142). January 2020 (PDF, 553Kb)
 Hepatobiliary Surgery, Service Specification (CP73). November 2021 (PDF, 344Kb)
 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei, Commissioning Policy (CP02). September 2015 (PDF, 301Kb)
 Lutetium (177Lu) oxodotreotide for people with neuroendocrine tumours (NETs), Policy Position Statement, (PP195). September 2020 (PDF, 367Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Commissioning Policy (CP87b). August 2015 (PDF, 501Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Service Specification (CP87a). August 2015 (PDF, 380Kb)
 Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification, (CP266), March 2023 (PDF, 300Kb)
 Plerixafor for stem cell mobilisation, Policy Position Statement (PP154), July 2023 (PDF, 256Kb)
 Positron Emission Tomography (PET) Commissioning Policy (CP50a), April 2023 (PDF, 356Kb)
 Positron Emission Tomography (PET), Service Specification (CP50b). September 2020 (PDF, 514Kb)
 Proton Beam Therapy for adults with cancer Commissioning Policy (CP147), July 2023 (PDF, 279Kb)
 Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148). April 2023 (PDF, 231Kb)
 Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Commissioning Policy (CP183a). May 2020 (PDF, 318Kb)
 Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Service Specification (CP183b). May 2020 (PDF, 348Kb)
 Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173). June 2020 (PDF, 188Kb)
 Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma, Policy Position Statement, (PP227). November 2021 (PDF, 303Kb)
 Soft Tissue Sarcoma, Service Specification (CP149). June 2020 (PDF, 396Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for the management of Non-Small Cell Lung Cancer in people aged 18 years and above, Commissioning Policy (CP76) June 2023 (PDF, 525Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) Service Specification (CP219) June 2021 (PDF, 356Kb)
 Stereotactic ablative radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (Adults), Commissioning Policy (CP124), December 2021 (PDF, 398Kb)
 Stereotactic Ablative Radiotherapy (SABR) in the treatment of Oligometastatic disease, Commissioning Policy (CP121). October 2021 (PDF, 387Kb)